Phenotypes associated with this allele

• Allele Symbol: Rnf186^em1Ktak
• Allele Name: endonuclease-mediated mutation 1, Kiyoshi Takeda
• Allele ID: MGI:6343557
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Rnf186^em1Ktak/Rnf186^em1Ktak	involves: C57BL/6 * DBA/2	MGI:6362821

Genotype
MGI:6362821

hm1

• Allelic Composition: Rnf186^em1Ktak/Rnf186^em1Ktak
• Genetic Background: involves: C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

digestive/alimentary system

abnormal intestine physiology ( J:258197 )

• at 6 weeks of age, mice show enhanced uptake of Lucifer yellow in colonic epithelial cells relative to wild-type controls

increased enterocyte apoptosis ( J:258197 )

• DSS-treated mice show significantly higher numbers of TUNEL-positive cells in colonic epithelial cells than DSS-treated wild-type controls at 5 days after treatment

increased susceptibility to induced colitis ( J:258197 )

• following oral administration of dextran sulfate sodium (DSS), mice show more severe weight loss and a reduced survival rate, with a significantly higher colitis score than DSS-treated wild-type controls at 8 days after treatment

increased susceptibility to colitis induced morbidity/mortality ( J:258197 )

• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 10 to 14 days after treatment

cellular

increased enterocyte apoptosis ( J:258197 )

• DSS-treated mice show significantly higher numbers of TUNEL-positive cells in colonic epithelial cells than DSS-treated wild-type controls at 5 days after treatment

increased endoplasmic reticulum stress ( J:258197 )

• DSS-treated mice exhibit enhanced ER stress in colonic epithelial cells, as shown by markedly increased expression of GRP7, CHOP and spliced XBP1 (sXBP1) at 6 days after treatment

mortality/aging

increased susceptibility to colitis induced morbidity/mortality ( J:258197 )

• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 10 to 14 days after treatment

increased susceptibility to xenobiotic induced morbidity/mortality ( J:258197 )

• following i.p. injection of tunicamycin (an ER stress inducer), 8-12-wk-old mice show a significantly lower survival rate than tunicamycin-treated wild-type controls at 96 h after challenge

immune system

increased susceptibility to induced colitis ( J:258197 )

• following oral administration of dextran sulfate sodium (DSS), mice show more severe weight loss and a reduced survival rate, with a significantly higher colitis score than DSS-treated wild-type controls at 8 days after treatment

increased susceptibility to colitis induced morbidity/mortality ( J:258197 )

• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 10 to 14 days after treatment

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:258197 )

• following i.p. injection of tunicamycin (an ER stress inducer), 8-12-wk-old mice show a significantly lower survival rate than tunicamycin-treated wild-type controls at 96 h after challenge